COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19
AssigneeTevogen Bio Inc.
InventorRyan Saadi
Life of this patent
Estimating the term…
Abstract
The invention relates to pharmaceutical compositions that contain COVID-19 peptide specific cytotoxic T cells, and to methods for treating or preventing COVID-19 infection.
Claims17
A method of treating COVID-19 infection, comprising administering to a human patient in need thereof an effective amount of cells comprising COVID-19 peptide specific cytotoxic T lymphocytes (CTLs) that are specifically enriched cells reactive to COVID-19 peptides, wherein said CTLs are sensitized against multiple peptides restricted against a single HLA allele by in vitro stimulation, wherein at least 20% of said CTLs are reactive to COVID-19 peptides, and wherein said cells comprise less than 2.5% of naïve T cells, monocytes, NK cells, or any combination thereof.
A method of preparing COVID-19 peptide specific cytotoxic T cells (CTLs) that are specifically enriched cells reactive to COVID-19 peptide comprising:
- a. a first stimulation step, whereby a subset of monocytes are treated to induce maturation into dendritic cells, the dendritic cells are pulsed with one or more COVID-19 specific peptides and co-cultured with lymphocytes for at least six days;
- b. a second stimulation step, whereby monocytes are used to present the COVID-19 specific peptides, stimulated lymphocytes are cultured for at least seven days, peptide specific CTLs are selected due to preferential adherence of T cells recognizing the pulse peptides to an adherent monocyte layer;
- and
- c. a third stimulation step, whereby a subset of monocytes are pulsed with multiple COVID-19 specific peptides restricted against a single HLA allele;
- thereby producing COVID-19 specific CTLs, wherein at least 20% of the CTLs are reactive to COVID-19 peptides.
Dependencies are inferred from the claim text.